DPP-4 inhibitors, commonly known as gliptins, prevent DPP-4 activity to inhibit the rapid breakdown of endogenously generated GLP-1, consequently promoting glucose regulation without generating hypoglycemia. This evidence concerns the gene DPP4 and Hypoglycemia.